| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Alligator Bioscience AB GAAP EPS of -SEK 0.34, revenue of SEK 0.47M | 3 | Seeking Alpha | ||
| Do | Alligator Bioscience AB Reports Financial Results for Q3 2025 and Provides a Business Update | 207 | ACCESS Newswire | Upcoming rights issue of approx. SEK 120 million (gross), providing 6-9 months of financial runway during 2026, announced 22 OctoberSuccessful warrant program TO 13 raises SEK 28.1 million (gross)Final... ► Artikel lesen | |
| Do | Notice of Extraordinary General Meeting in Alligator Bioscience AB | 275 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 22, 2025 / Alligator Bioscience (STO:ATORX)The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation... ► Artikel lesen | |
| ALLIGATOR BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| Mi | Alligator Bioscience Carries Out a Rights Issue of Units of Approximately SEK 120 Million and Raises Bridge Loans | 285 | ACCESS Newswire | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 21.10. | Alligator Bioscience Granted US Patent Covering ATOR-4066 Bispecific Antibody | 209 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 21, 2025 / Alligator Bioscience (Nasdaq Stockholm: ATORX)(STO:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs... ► Artikel lesen | |
| 16.10. | Invitation to Alligator Bioscience's Earnings Call on 23 October 2025 | 172 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 16, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX)(STO:ATORX) ), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody... ► Artikel lesen | |
| 13.10. | Alligator Bioscience: REACtiVe-2 Phase 1 Data Featuring Mitazalimab Demonstrate Immune Activation in Metastatic Pancreatic Cancer - To be Presented at ESMO 2025 | 217 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 13, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX)(STO:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs... ► Artikel lesen | |
| 08.10. | Alligator Bioscience: Alligator Announces Publication of OPTIMIZE-1 Biomarker Analysis in Cell Reports Medicine Supporting mitazalimab and mFOLFIRINOX in Metastatic Pancreatic Cancer | 176 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 8, 2025 / Alligator Bioscience (Nasdaq Stockholm: ATORX)(STO:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs... ► Artikel lesen | |
| 06.10. | Alligator Bioscience Announces Acceptance of Two Abstracts at SITC 40th Anniversary Annual Meeting | 171 | ACCESS Newswire | LUND, SWEDEN / ACCESS Newswire / October 6, 2025 / Alligator Bioscience (STO:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced... ► Artikel lesen | |
| 22.09. | Alligator Bioscience: Alligator Announces Final 30-Month OPTIMIZE-1 Results Highlighting the Potential of Mitazalimab in Metastatic Pancreatic Cancer | 220 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 22, 2025 / Alligator Bioscience (STO:ATORX)(Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody... ► Artikel lesen | |
| 17.09. | Alligator Bioscience AB Announces Final Outcome of Exercise of Warrants Series TO 13 | 258 | ACCESS Newswire | LUND, SWEDEN / ACCESS Newswire / September 17, 2025 / Alligator Bioscience (STO:ATORX)NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS... ► Artikel lesen | |
| 16.09. | Alligator Bioscience AB Announces Preliminary Outcome of Exercise of Warrants Series TO 13 | 263 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 16, 2025 / Alligator Bioscience (STO:ATORX)NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS... ► Artikel lesen | |
| 12.09. | Alligator Bioscience: Alligator to Present New Preclinical Results on ATOR-4066 at CICON25 | 306 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 12, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, announced... ► Artikel lesen | |
| 11.09. | Last Day of Trading in Warrants Series TO 13 in Alligator Bioscience is 11 September 2025 | 282 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 11, 2025 / Alligator Bioscience (STO:ATORX)NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA... ► Artikel lesen | |
| 10.09. | Alligator Bioscience: Alligator Announces Publication in Cancer Immunology Research of Preclinical Data on ATOR-4066, a Tumor-Directed CD40×CEACAM5 Bispecific Antibody | 280 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 10, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today... ► Artikel lesen | |
| 09.09. | Alligator Bioscience Has Renegotiated the Outstanding Loan From Fenja Capital and Received Subscription Intentions From Members of the Board of Directors and Management | 380 | ACCESS Newswire | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH... ► Artikel lesen | |
| 08.09. | Alligator Bioscience: Grant Awarded to Investigator-Initiated Phase 2/3 Trial with Mitazalimab in Biliary Tract Cancer | 300 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 8, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today... ► Artikel lesen | |
| 05.09. | Alligator Bioscience to present at BioStock's "Investing in Life Science" event | 262 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 5, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today... ► Artikel lesen | |
| 02.09. | Alligator Bioscience: Alligator Announces Evaluation and Option Agreement Covering RUBY Antibody Format | 286 | ACCESS Newswire | LUND, SWEDEN / ACCESS Newswire / September 2, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX) today announced that Alligator has entered into an evaluation and option agreement with an infectious... ► Artikel lesen | |
| 27.08. | Exercise Price Determined for the Exercise of Warrants Series TO 13 in Alligator Bioscience AB | 330 | ACCESS Newswire | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,70 | -0,38 % | BioNTech startet milliardenschweres Umtauschangebot für CureVac-Aktien | BioNTech hat das öffentliche Umtauschangebot für alle ausstehenden Aktien von CureVac N.V. gestartet. Das Angebot basiert auf dem Kaufvertrag vom 12. Juni 2025 und sieht vor, dass jede CureVac-Aktie... ► Artikel lesen | |
| EVOTEC | 7,074 | -0,70 % | Aktien Frankfurt: Solide Zahlen aus den USA schieben Kurse an | FRANKFURT (dpa-AFX) - Überwiegend robuste Quartalsbilanzen und Prognosen von US-Unternehmen haben dem deutschen Aktienmarkt am Dienstag etwas Anschub verliehen. Der Leitindex Dax, der sich bis zum... ► Artikel lesen | |
| BB BIOTECH | 43,950 | -0,45 % | EQS-Adhoc: BB BIOTECH AG: BB Biotech AG veröffentlicht Zwischenbericht | EQS-Ad-hoc: BB BIOTECH AG / Schlagwort(e): Zwischenbericht
BB Biotech AG veröffentlicht Zwischenbericht
24.10.2025 / 07:00 CET/CEST
Veröffentlichung einer Insiderinformation nach Artikel... ► Artikel lesen | |
| MEDIGENE | 0,055 | -7,69 % | Medigene: Gericht eröffnet Insolvenzverfahren | Bei Medigene geht die Insolvenz ihren Weg: Das zuständige Amtsgericht in München hat nach Angaben der Gesellschaft vom Freitag heute das Insolvenzverfahren über das Vermögen der Medigene AG sowie der... ► Artikel lesen | |
| QIAGEN | 41,140 | -1,72 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| CUREVAC | 4,578 | -0,56 % | BionTech Aktie startet Übernahme von CureVac - Jetzt Aktien kaufen? | ||
| MODERNA | 22,495 | -2,39 % | BioNTech-Konkurrent Moderna: Studie gescheitert, Aktie unter Druck | Die Aktie von Moderna steht heute deutlich unter Druck. Grund sind Phase-3-Daten, die das Unternehmen am Mittwoch nach US-Börsenschluss veröffentlicht hat. Der Zytomegalievirus-(CMV)-Impfstoffkandidat... ► Artikel lesen | |
| VALNEVA | 3,918 | +0,10 % | Valneva-Aktie im Mittelpunkt - Experten erwarten bald starke Reaktion! | ||
| AMGEN | 249,95 | -0,14 % | AstraZeneca And Amgen's Tezspire Approved In EU For Severe Nasal Polyps | THOUSAND OAKS (dpa-AFX) - AstraZeneca (AZN) and Amgen (AMGN) announced that Tezspire (tezepelumab) has received European Union approval as an add-on therapy with intranasal corticosteroids for... ► Artikel lesen | |
| EPIGENOMICS | 0,890 | 0,00 % | PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Epigenomics... ► Artikel lesen | |
| NOVAVAX | 7,311 | -1,87 % | Novavax, Inc.: Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy | Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million... ► Artikel lesen | |
| BIOGEN | 128,60 | -0,85 % | Biogen Inc.: Health Canada Grants Authorization for "LEQEMBI" (lecanemab) for the Treatment of Early Alzheimer's Disease | TOKYO and CAMBRIDGE, Mass., Oct. 26, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts... ► Artikel lesen | |
| BIOFRONTERA | 2,780 | +4,12 % | Biofrontera trennt sich vom US-Geschäft | Das Leverkusener Biopharma-Unternehmen hat seine amerikanischen Aktivitäten verkauft. Die Transaktion soll Kosten senken und Risiken eliminieren. Doch was bleibt übrig? Klarer Schnitt mit Folgen: Die... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,920 | -4,58 % | Heidelberg Pharma erhält Fast-Track-Status der FDA für HDP-101 | Die Heidelberg Pharma AG aus Ladenburg hat von der US-amerikanischen Food and Drug Administration (FDA) den Fast-Track-Status für ihren führenden Antikörper-Wirkstoff-Konjugat-Kandidaten HDP-101 erhalten.... ► Artikel lesen | |
| ILLUMINA | 84,70 | -1,66 % | Biotech-Wende: Nach 4 Jahren Crash: Illumina-Aktie vor massivem Kaufsignal | Die Aktie des Krebsforschungsspezialisten Illumina steckt seit Jahren in einem Abwärtstrend. Doch nun mehren sich die Anzeichen für eine Trendwende. Die Aktie hat die Mehrjahrestiefs hinter sich gelassen... ► Artikel lesen |